TFF Pharmaceuticals expands its cGMP manufacturing capabilities

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has expanded its engagement with contract manufacturing organization (CMO) Experic, LLC to install its patented thin film freezing (TFF) processing line and associated capabilities at the CMO’s cGMP facility in Cranbury, NJ.

Installation of the custom-designed equipment is expected to be completed in early Q2 2021. It will increase TFF’s manufacturing capacity, as well as provide a third cGMP manufacturing location for the company.

The thin film freezing platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung.

“This expansion of our manufacturing operations at Experic gives us the capability and capacity to develop and produce additional products currently in assessment with pharmaceutical company partners,” said Glenn Mattes, president and CEO of TFF Pharmaceuticals.

He added that Experic’s domain expertise in dry powder inhalation products and downstream encapsulation technology rounds out the specialized manufacturing requirements of TFF’s dry powder inhalation therapies.

Experic supports product life cycle from clinical to commercial scale, across a range of dosing and packaging formats, including capsule filling, powder and pellet dosing (including DPI), and autoinjectors and pen assemblies. 

TFF Pharmaceuticals is focused on developing and commercializing drug products based on its TFF technology platform.